| Literature DB >> 28748764 |
Effimia Zacharia1, Nikolaos Papageorgiou2, Adam Ioannou3, Gerasimos Siasos1, Spyridon Papaioannou1, Manolis Vavuranakis1, George Latsios1, Charalampos Vlachopoulos1, Konstantinos Toutouzas1, Spyridon Deftereos4, Rui Providência2, Dimitris Tousoulis1.
Abstract
During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Atrial fibrillation; C-reactive protein; anti-inflammatory drugs; inflammation; inflammatory biomarkers; interleukins; statins.
Mesh:
Substances:
Year: 2019 PMID: 28748764 DOI: 10.2174/0929867324666170727103357
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530